Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Karyopharm Therapeutics Inc. (KPTI) had Return on Equity of 34.89% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$34.08M |
|
$-102.20M |
|
$1.48M |
|
$32.59M |
|
$51.92M |
|
$-17.84M |
|
$-84.42M |
|
$-102.27M |
|
$-102.27M |
|
$-102.20M |
|
$-102.20M |
|
$-102.20M |
|
$-102.20M |
|
$-17.84M |
|
$-15.39M |
|
10.94M |
|
10.94M |
|
$-7.02 |
|
$-7.02 |
|
| Balance Sheet Financials | |
$103.15M |
|
$0.10M |
|
$5.27M |
|
$108.42M |
|
$92.06M |
|
$205.88M |
|
$309.28M |
|
$401.34M |
|
$-292.93M |
|
$-292.93M |
|
$-292.93M |
|
18.31M |
|
| Cash Flow Statement Financials | |
$-75.37M |
|
$43.38M |
|
$30.05M |
|
$62.81M |
|
$60.89M |
|
$-1.92M |
|
$14.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.12 |
|
-- |
|
-- |
|
-2.37 |
|
-0.77 |
|
95.65% |
|
-52.36% |
|
-52.36% |
|
-- |
|
-300.08% |
|
-299.89% |
|
$-75.37M |
|
-- |
|
-- |
|
-- |
|
0.31 |
|
0.37 |
|
1.30 |
|
69.13 |
|
|
Return on Equity |
34.89% |
34.89% |
|
-94.26% |
|
117.41% |
|
$-16.00 |
|
$-6.89 |
|
$-6.89 |
|